NCT07048249 2026-03-18
Single Arm Romiplostim to Prevent CIT
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Recruiting
Clinical Trials
40 trialsNCT07194044 2026-03-16
METTSEO
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT07297979 2026-03-16
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Amgen
Phase 1 Recruiting
NCT01804634 2026-03-13
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT06395103 2026-03-11
MK-9999-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06625190 2026-03-11
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
University of Florida
Phase 1/2 Recruiting
NCT06541262 2026-03-02
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Milton S. Hershey Medical Center
Phase 1/2 Recruiting
NCT04851119 2026-02-24
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
Phase 1/2 Recruiting
NCT05918640 2026-02-23
LiFFT
Children's Hospital of Philadelphia
Phase 1/2 Recruiting
NCT06709495 2026-02-19
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT07197554 2026-02-18
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics, Inc.
Phase 1 Recruiting
NCT04055220 2026-02-17
REGOSTA
Centre Leon Berard
Phase NA Recruiting
NCT04901702 2026-02-09
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT06387485 2026-02-06
A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning
Ricoh USA, Inc.
Phase NA Recruiting
NCT05734066 2026-02-03
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Jazz Pharmaceuticals
Phase 1/2 Recruiting
NCT07172958 2026-01-27
SABRE
Children's National Research Institute
Phase 1 Recruiting
NCT07188532 2026-01-23
BEAR
Mayo Clinic
Phase NA Recruiting
NCT04995003 2026-01-22
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Baylor College of Medicine
Phase 1 Recruiting
NCT06068075 2026-01-22
Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD
Dana-Farber Cancer Institute
Phase NA Recruiting
NCT05046314 2026-01-14
A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 2 Recruiting
NCT06156410 2025-11-14
Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas
Children's Hospital of Philadelphia
Phase 1 Recruiting
NCT04084067 2025-11-04
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04897321 2025-10-24
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT02508038 2025-10-16
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
Phase 1 Recruiting
NCT04337177 2025-09-23
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Recruiting
NCT06926283 2025-09-17
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT05135975 2025-08-12
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
Nationwide Children's Hospital
Phase 2 Recruiting
NCT07066982 2025-07-15
BAH2573-103
Essen Biotech
Phase 1/2 Recruiting
NCT06566092 2025-06-29
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
Iovance Biotherapeutics, Inc.
Phase 1 Recruiting
NCT06827717 2025-05-31
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06796543 2025-04-17
TARGET-RT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Recruiting
NCT05968768 2025-04-10
To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)
Institute of Mother and Child, Warsaw, Poland
Phase 2 Recruiting
NCT05210374 2025-03-25
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT06094101 2024-12-12
PerVision
University Hospital Tuebingen
Phase 1/2 Recruiting
NCT06699472 2024-11-21
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
Fudan University
Phase 2 Recruiting
NCT06029218 2024-09-25
P1V2
Centre Antoine Lacassagne
Phase NA Recruiting
NCT06564272 2024-08-23
A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
Beijing Konruns Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06340204 2024-04-03
Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Peking University People's Hospital
Phase 1 Recruiting
NCT05328258 2023-10-27
ProFertil
Karolinska University Hospital
Phase 3 Recruiting
NCT04758000 2023-08-04
Metform-Bone
Istituto Ortopedico Rizzoli
Phase 2 Recruiting